Nektar Therapeutics (NKTR) executive compensation, 2026 proxy

Howard W. Robin, President and Chief Executive Officer, was paid $6.3M in 2025, up 66% from $3.8M the year before.

Filed
April 24, 2026
Annual meeting
June 4, 2026
Pay year
2025
Named executives
4
CEO total pay
$6.3M+66% vs prior year
CEO pay in equity
63%$3.9M in awards
CEO Target Bonus
100%Percentage of base salary
Stock and Option Awards
$3,928,616CEO equity awards for 2025
Non-Equity Incentive
$1,106,282CEO annual incentive payout
Plan Increase
3,000,000Shares added to incentive plan

How Robin was paid

$6.3M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.

Salary18%Stock awards15%Option awards48%Non-equity incentive18%All other compensation2%

Named executive officers

ExecutiveTotal
Howard W. RobinPresident and Chief Executive Officer$6,256,954
Sandra GardinerInterim Chief Financial Officer$686,400
Mark A. WilsonFormer Chief Legal Officer$667,901
Jonathan Zalevsky, Ph.D.Chief Research and Development Officer$2,320,358

What changed and why

  • $6.3MHoward W. Robin total compensation increased to $6,256,954 in 2025 from $3,762,693 in 2024.
  • Fifty percent of annual stock awards granted to NEOs in 2025 were performance-based.
  • Performance-based RSUs require achieving full enrollment in Phase 3 rezpegaldesleukin studies.
  • Mark A. Wilson served as Chief Legal Officer until December 31, 2025.
  • Sandra Gardiner served as Interim Chief Financial Officer through FLG Partners consulting agreement.

About this page

Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.